Skip to main content
. 2021 Feb 24;106(8):e3221–e3234. doi: 10.1210/clinem/dgab108

Figure 4.

Figure 4.

Menstrual cycle length and biochemical parameters of ovulation in women receiving placebo or elinzanetant during the study. A, The change in menstrual cycle length between cycles 1 (C1) and 2 (C2) after treatment with placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange) in healthy women. Data in graphs depict within-participant paired raw data and the group median and interquartile range. *P less than .05, Wilcoxon rank sum test. B, The median change between cycles 1 and 2 in menstrual cycle length (days) in healthy women after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). *P less than .05, Wilcoxon rank sum test. C, The percentage of healthy women with a serum progesterone greater than 30 nmol/L in cycle 2 after placebo (N = 8, red), elinzanetant 40 mg (N = 7, blue), 80 mg (N = 8, green), and 120 mg (N = 8, orange). **P less than .01, chi-square test.